跳至主要内容
临床试验/ACTRN12605000394640
ACTRN12605000394640
招募中
4 期

Treatment of Schizophrenia with Aripiprazole. A one year open-label study examining an ultraslow switchover regime to minimise relapse and withdrawal symptoms.

Associate Professor Krishna Vaddadi0 个研究点目标入组 40 人2005年9月14日

概览

阶段
4 期
干预措施
未指定
疾病 / 适应症
Schizophrenia
发起方
Associate Professor Krishna Vaddadi
入组人数
40
状态
招募中
最后更新
6年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
2005年9月14日
结束日期
待定
最后更新
6年前
研究类型
Interventional
性别
All

研究者

发起方
Associate Professor Krishna Vaddadi

入排标准

入选标准

  • Patients who are outpatients (private or public) attending southern health facility and have a well established diagnosis of schizophrenia (DSM\-IV diagnosis criteria), who report side effects on their existing medication, who have not fully responded to their current therapy, who in the clinicians opinion, would benefit from Aripiprazole, who are able to comprehend what is happening to them and able to give informed consent, who can speak a reasonable level of English, and where completing rating scales with adequate information is not a practical problem.

排除标准

  • Patients who want to become pregnant during the study period, with alcohol dependence, with acquired brain injury associated with schizophrenia, who are on too complex medication regimes which would be difficult to change, who have previously been treated with Aripiprazole, who are on very high doses of clozapine in (\>500mg/day), on very high doses of injectable Zuclopenthixol Decanoate (\>200mg/fortnight), with a past history of severe violence/suicidal risk, who are generally non\-compliant with oral medication, who have poor social supports and are very unreliable with appointments, and patients who are very stable on their current antipsychotic medication, but want to change to Aripiprazole simply because it is a new drug, their friend got better or, someone told them it is a good idea.

结局指标

主要结局

未指定

相似试验